Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations

Thoratec Corporation THOR, a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that revenues from continuing operations in fiscal 2010 increased 37 percent over those in fiscal 2009. Results from continuing operations for both the full year and fourth quarter of fiscal 2010 and 2009 exclude contributions from the company's International Technidyne Corporation (ITC) Division. Thoratec completed the divestiture of ITC in November 2010. For the year ended January 1, 2011, revenues were $383.0 million versus $280.0 million in the prior year. Revenues for the fourth quarter of fiscal 2010 were $97.6 million, an increase of 20 percent over revenues of $81.0 million in the fourth quarter of fiscal 2009.